Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD).

MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization in Age-Related Macular Degeneration) evaluated drugs, including ranibizumab, for the treatment of AMD and other forms of MD.

http://www.bioopticsworld.com/news/2011/10/1530123521/mayo-clinic-work-shows-possible-lucentis-side-effect.html

Similar Posts

Metformin use associated with reduced risk of developing open-angle glaucoma

ByConnor Hodde

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology. Medications that mimic caloric restriction such as metformin can reduce the risk of some late age-onset disease. It is unknown whether these caloric mimetic drugs…

AMD-Risk Genes: Global Collaborative Finds 7 New Sites

ByConnor Hodde

An international research collaborative has identified 7 new genetic loci associated with an increased risk of developing age-related macular degeneration (AMD), bringing the total number of known AMD-susceptibility loci in the human genome to 19. Scientists from 18 research groups in 14 countries formed the consortium in the spring of 2010 with the goal of…

Nanotechnology Paves the Way for Advances in Genome Sequencing

ByConnor Hodde

The first human genome sequencing was accomplished after 13 painstaking years of research at the cost of $3 billion. But recent advances in sequencing technology holds promise of rapid increase in speed of sequencing at the rate of 6 billion nucleotide bases every 6 h at a cost below $1000. http://www.azonano.com/news.aspx?newsID=24912

Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments

ByConnor Hodde

Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing.  Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications.   eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…

ByConnor Hodde

Retinitis pigmentosa, a blinding eye disease that is caused by the same genetic defect in both dogs and humans, was successfully corrected by a University of Pennsylvania research team that used gene therapy in afflicted dogs. The retinitis pigmentosa cure holds promise for eventual treatment in humans as well. Both humans and dogs can contract…